Last reviewed · How we verify
Norepinephrine 6 mcg
Norepinephrine 6 mcg, marketed by Cairo University, is a drug with a key composition patent expiring in 2028. The primary strength of Norepinephrine 6 mcg lies in its established market presence, supported by its current marketed status. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Norepinephrine 6 mcg |
|---|---|
| Also known as | Levophed |
| Sponsor | Cairo University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparing Two Different Norepinephrine Infusion Rates for Prophylaxis Against Spinal-induced Hypotension in Elderly (NA)
- Hemodynamics During Cesarean Delivery Under Spinal Anesthesia With Norepinephrine Versus Ephedrine (PHASE4)
- Early Intravenous Hydrocortisone in Sepsis (NA)
- POCUS-Guided Esmolol in Septic Shock: A Pilot RCT (PHASE1, PHASE2)
- Sex Disparities in Hypoxic Vasodilation and Impact of Obesity (EARLY_PHASE1)
- Fluid Responsiveness in Posterior Fossa Tumor Resection: PPV and CVP Guidance (NA)
- Comparison of Two Different Norepinephrine Bolus Doses for Management of Spinal Anesthesia-Induced Maternal Hypotension (PHASE4)
- Propranolol as an Anxiolytic to Reduce the Use of Sedatives From Critically-ill Adults Receiving Mechanical Ventilation (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Norepinephrine 6 mcg CI brief — competitive landscape report
- Norepinephrine 6 mcg updates RSS · CI watch RSS
- Cairo University portfolio CI